Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$42.13K$42.13Kderivedno prior Q4 2017 on file Net Income$1.38M$1.38Mderived−21.9% vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$34,063— Operating Incomederived-$1,032,047N/M Operating Cash Flowderived-$716,095N/M Free Cash Flowderived-$716,095— Margins · derivedGross margin80.9%
Operating margin-2449.6%
Net margin3280.5%
ended Dec 31, 2018 · filed Apr 15, 2019 · 105 d after period end